PLIANT THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
PLRX$0.80-1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
| AdditionalPaid-InCapital · AccumulatedOtherComprehensive(Loss) Gain · AccumulatedDeficit · TotalStockholders'Equity | ||||||
|---|---|---|---|---|---|---|
| Common Stock | ||||||
| Shares · Amount | ||||||
| Balance at December 31, 2020 | 35,552,795 | $3 | $400,918 | $(32) | $(117,828) | $283,061 |
| Issuance of common stock under benefit plans | 427,342 | — | 2,984 | — | — | 2,984 |
| Vesting of restricted stock awards | 103,164 | — | 9 | — | — | 9 |
| Stock-based compensation expense | — | — | 10,437 | — | — | 10,437 |
| Net unrealized loss on short-term investments | — | — | — | (169) | — | (169) |
| Net loss | — | — | — | — | (97,263) | (97,263) |
| Balance at December 31, 2021 | 36,083,301 | $3 | $414,348 | $(201) | $(215,091) | $199,059 |
| Common stock issued in a public offering, net of offering expenses | 12,432,432 | 2 | 215,399 | — | — | 215,401 |
| Issuance of common stock under benefit plans | 403,680 | — | 1,360 | — | — | 1,360 |
| Vesting of restricted stock awards | 21,841 | — | 2 | — | — | 2 |
| Stock-based compensation expense | — | — | 22,598 | — | — | 22,598 |
| Net unrealized loss on short-term investments | — | — | — | (1,757) | — | (1,757) |
| Net loss | — | — | — | — | (123,321) | (123,321) |
| Balance at December 31, 2022 | 48,941,254 | $5 | $653,707 | $(1,958) | $(338,412) | $313,342 |
| Common stock issued in a public offering, net of offering expenses | 9,583,334 | 1 | 269,781 | — | — | 269,782 |
| Issuance of common stock under benefit plans | 1,396,414 | — | 5,002 | — | — | 5,002 |
| Stock-based compensation expense | — | — | 44,483 | — | — | 44,483 |
| Net unrealized gain on short-term investments | — | — | — | 2,303 | — | 2,303 |
| Net loss | — | — | — | — | (161,336) | $(161,336) |
| Balance at December 31, 2023 | 59,921,002 | $6 | $972,973 | $345 | $(499,748) | $473,576 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.